Literature DB >> 22948889

Pharmacogenomics and individualized medicine: translating science into practice.

K R Crews1, J K Hicks, C-H Pui, M V Relling, W E Evans.   

Abstract

Research on genes and medications has advanced our understanding of the genetic basis of individual drug responses. The aim of pharmacogenomics is to develop strategies for individualizing therapy for patients, in order to optimize outcome through knowledge of the variability of the human genome and its influence on drug response. Pharmacogenomics research is translational in nature and ranges from discovery of genotype-phenotype relationships to clinical trials that can provide proof of clinical impact. Advances in pharmacogenomics offer significant potential for subsequent clinical application in individual patients; however, the translation of pharmacogenomics research findings into clinical practice has been slow. Key components to successful clinical implementation of pharmacogenomics will include consistent interpretation of pharmacogenomics test results, availability of clinical guidelines for prescribing on the basis of test results, and knowledge-based decision support systems.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948889      PMCID: PMC3589526          DOI: 10.1038/clpt.2012.120

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  71 in total

1.  Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.

Authors:  Laura B Ramsey; Gitte H Bruun; Wenjian Yang; Lisa R Treviño; Selina Vattathil; Paul Scheet; Cheng Cheng; Gary L Rosner; Kathleen M Giacomini; Yiping Fan; Alex Sparreboom; Torben S Mikkelsen; Thomas J Corydon; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Genome Res       Date:  2011-12-06       Impact factor: 9.043

2.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

3.  Sequencing set to alter clinical landscape.

Authors:  Erika Check Hayden
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

4.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

5.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

6.  Putting pharmacogenetics into practice.

Authors:  Michael M Hopkins; Dolores Ibarreta; Sibylle Gaisser; Christien M Enzing; Jim Ryan; Paul A Martin; Graham Lewis; Symone Detmar; M Elske van den Akker-van Marle; Adam M Hedgecoe; Paul Nightingale; Marieke Dreiling; K Juliane Hartig; Wieneke Vullings; Tony Forde
Journal:  Nat Biotechnol       Date:  2006-04       Impact factor: 54.908

Review 7.  Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.

Authors:  A R Hughes; W R Spreen; M Mosteller; L L Warren; E H Lai; C H Brothers; C Cox; A J Nelsen; S Hughes; D E Thorborn; B Stancil; S V Hetherington; D K Burns; A D Roses
Journal:  Pharmacogenomics J       Date:  2008-03-11       Impact factor: 3.550

Review 8.  Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?

Authors:  A E Shields; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

9.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

Review 10.  Candidate gene identification approach: progress and challenges.

Authors:  Mengjin Zhu; Shuhong Zhao
Journal:  Int J Biol Sci       Date:  2007-10-25       Impact factor: 6.580

View more
  81 in total

1.  Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations.

Authors:  John Jack; Tammy M Havener; Howard L McLeod; Alison A Motsinger-Reif; Matthew Foster
Journal:  Pharmacogenomics       Date:  2015-08-28       Impact factor: 2.533

2.  The role of pharmacogenomic biomarkers in predicting and improving drug response: part 2: challenges impeding clinical implementation.

Authors:  C Lee Ventola
Journal:  P T       Date:  2013-10

Review 3.  Bringing genome-wide association findings into clinical use.

Authors:  Teri A Manolio
Journal:  Nat Rev Genet       Date:  2013-07-09       Impact factor: 53.242

Review 4.  A 50-year journey to cure childhood acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  Semin Hematol       Date:  2013-07       Impact factor: 3.851

5.  A taste of individualized medicine: physicians' reactions to automated genetic interpretations.

Authors:  Hallvard Lærum; Sara Bremer; Stein Bergan; Thomas Grünfeld
Journal:  J Am Med Inform Assoc       Date:  2013-09-03       Impact factor: 4.497

6.  Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants.

Authors:  C Lee Ventola
Journal:  P T       Date:  2013-09

7.  Implementation of a clinical research pharmacogenomics program at an academic medical center: role of the genetics healthcare professional.

Authors:  Amy Curry Sturm; Kevin Sweet; Kandamurugu Manickam
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

8.  Pharmacogenomics-based practice in North Cyprus: its adoption by pharmacists and their attitudes and knowledge.

Authors:  Louai Alsaloumi; Abdikarim Abdi; Özgür Tosun; Bilgen Başgut
Journal:  Int J Clin Pharm       Date:  2019-07-02

9.  Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing.

Authors:  James E Kimpton; Iain M Carey; Christopher J D Threapleton; Alexandra Robinson; Tess Harris; Derek G Cook; Stephen DeWilde; Emma H Baker
Journal:  Br J Clin Pharmacol       Date:  2019-12-13       Impact factor: 4.335

10.  The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.

Authors:  A R Shuldiner; M V Relling; J F Peterson; J K Hicks; R R Freimuth; W Sadee; N L Pereira; D M Roden; J A Johnson; T E Klein; Alan R Shuldiner; Mark Vesely; Shawn W Robinson; Nicholas Ambulos; Sanford A Stass; Mark D Kelemen; Lawrence A Brown; Toni I Pollin; Amber L Beitelshees; Richard Y Zhao; Ruth E Pakyz; Kathleen Palmer; Tameka Alestock; Courtney O'Neill; Kristin Maloney; Amie Branham; Danielle Sewell; Mary V Relling; Kristine Crews; James Hoffman; Shane Cross; Cyrine Haidar; Don Baker; J Kevin Hicks; Gillian Bell; Fran Greeson; Aditya Gaur; Ulrike Reiss; Alicia Huettel; Cheng Cheng; Amar Gajjar; Alberto Pappo; Scott Howard; Melissa Hudson; Ching-Hon Pui; Sima Jeha; William E Evans; Ulrich Broeckel; Russ B Altman; Li Gong; Michelle Whirl-Carrillo; Teri E Klein; Wolfgang Sadee; Kandamurugu Manickam; Kevin M Sweet; Peter J Embi; Dan Roden; Josh Peterson; Josh Denny; Jonathan Schildcrout; Erica Bowton; Jill Pulley; Marc Beller; Jennifer Mitchell; Ioana Danciu; Lisa Price; Naveen L Pereira; Richard Weinshilboum; Liewei Wang; Julie A Johnson; David Nelson; Michael Clare-Salzler; Amanda Elsey; Benjamin Burkley; Taimour Langaee; Felix Liu; David Nessl; Hui-Jia Dong; Larry Lesko; Robert R Freimuth; Christopher G Chute
Journal:  Clin Pharmacol Ther       Date:  2013-03-19       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.